Theraclone Sciences, a Seattle biotechnology company that’s developing a method to rapidly identify disease-fighting antivbodies, has attracted $10.6 million. Investors in the deal include ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo

Gillis

“The anticipated near-term initiation of Theraclone’s first clinical trial and our discovery collaboration with Pfizer earlier this year are important milestones that demonstrate Theraclone’s continued progress with our R&D pipeline and technology platform. The continued support from our investors represents both a vote of confidence and an ability to sustain our rapid pace of activity and progress,” said Steven Gillis, a venture capitalist at Arch Venture Partners who is serving as acting CEO.

Earlier this year, Theraclone scored a cancer research deal with drug giant Pfizer valued at as much as $632 million.

Founded as Spaltudaq in 2005 at the Seattle-based Accelerator, Theraclone has raised a total of $41 million in its second round of financing.

Like what you're reading? Subscribe to GeekWire's free newsletters to catch every headline

Comments

Job Listings on GeekWork

Find more jobs on GeekWork. Employers, post a job here.